We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New, Portable Lab-on-a-Chip Identifies Concentration of COVID-19 Antibodies in Human Blood In 15 Minutes

By LabMedica International staff writers
Posted on 01 Oct 2020
A new, portable lab-on-a-chip can identify the presence of COVID-19 antibodies in blood with greater speed and efficiency than the current standard “enzyme-linked immunosorbent assay” or ELISA technology.

Researchers from the University of Michigan (Ann Arbor, MI, USA) have developed the device and have shown that it can identify the concentration of COVID-19 antibodies in human blood in 15 minutes. More...
That process normally takes between hours and a few days. The device, which is actually a miniature ELISA, can achieve its faster results with smaller amounts of blood. The work has particular value for the validation of convalescent plasma as a treatment for COVID-19. Microfluidic devices shrink multiple lab functions onto a single chip measured in millimeters or centimeters. In addition to needing smaller sample sizes, they also increase accuracy. This particular system can detect concentration levels of antibodies -something that can vary greatly from plasma donor to donor.

Specifically, the device detects the presence and amount of neutralizing immunoglobulin -antibodies created by the immune system within seven to 10 days of a COVID-19 infection. Only donors with high levels are likely to provide samples that could be effective in treatment, such as convalescent plasma therapy. The treatment involves taking blood from subjects that have previously been diagnosed with COVID-19, and then separating out the plasma - the liquid portion of the blood that contains antibodies. Those antibodies are then given to patients therapeutically in an attempt to boost the immune response. To bolster the data available on convalescent plasma treatments, more donors with high-titer antibody concentrations are needed. The methodology developed by the University of Michigan team provides an efficient and effective way forward.

Screening for proper donors is typically handled by standard ELISA, which requires sample processing and a refrigerator-sized plate-reader for taking measurements. Delays are exacerbated by having to send samples to a lab for analysis. The lab-on-a-chip approach analyzes on site and delivers quantitative evaluations with finger prick’s worth of blood – eight microliters. A traditional ELISA machine requires 100 microliters to do its work. The system is contained in a device the size of a portable 3D printer.

“Convalescent plasma is a treatment that can be very effective – but for it to have the best chance to work, it needs to have rigorous standards, which include assessing the presence of high-titer neutralizing antibodies,” said David Perlin, Ph.D., chief scientific officer and senior vice president of the Hackensack Meridian Center for Discovery and Innovation, and one of the new study’s authors. “This paper shows how the antibody thresholds can mean a better potential COVID-19 treatment – and also better outcomes.”

Related Links:
University of Michigan


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Collection and Transport System
PurSafe Plus®
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.